Home » Authors » Rachelle H.B. Fishman

Articles by Rachelle H.B. Fishman

Israeli Biotech Continues Growth With Private, Government Support

May 7, 2003

By Rachelle H.B. Fishman

Ester Neuroscience Gets Good Results In Early Antisense Trial

April 9, 2003

By Rachelle H.B. Fishman

Chiasma Gets First Biotech Investment From InnoMed

April 9, 2003

By Rachelle H.B. Fishman

Bioline Therapeutics Formed By Israeli Groups With $11M Funding

April 9, 2003

By Rachelle H.B. Fishman

Gamida-Cell, Teva Enter Deal To Develop Stem Cell Product

March 26, 2003

By Rachelle H.B. Fishman

MediWound's Burn Agent Gains Orphan Status, Starts Phase IIb

March 5, 2003

By Rachelle H.B. Fishman

Ester Neuroscience Successfully Delivers Antisense Drug Orally

Jan. 8, 2003

By Rachelle H.B. Fishman

Founders Staying In Israel As Keryx Moves Operations To U.S.

Jan. 1, 2003

By Rachelle H.B. Fishman

Japanese, Israeli Firms Unite On Tyrosine Kinase Blockers

Dec. 11, 2002

By Rachelle H.B. Fishman

Competitors Managing Israel's First Private Biotech Incubators

Dec. 4, 2002

By Rachelle H.B. Fishman

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 16, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Anti-C5aR1 antibodies linked to outcomes in giant cell arteritis
BioWorld Science
More effective glucocorticoid-sparing therapies are needed for the treatment of giant cell arteritis (GCA). Studies found that complement signaling pathways...
Fortvita and Innovent patent new anti-TROP2/B7-H4 ADCs
BioWorld Science
Fortvita Biologics Inc. and Innovent Biologics (Suzhou) Co. Ltd. have jointly reported new antibody-drug conjugates (ADCs) comprising a bispecific antibody or...